Iressa (Gefitinib) 250 mg – Targeted Therapy for Lung Cancer Iressa (Gefitinib)

Iressa (Gefitinib) is a targeted therapy used in the treatment of non-small cell lung cancer (NSCLC), especially in patients with EGFR mutations.

What is Iressa (Gefitinib)?

Iressa belongs to a class of drugs called Tyrosine Kinase Inhibitors (TKIs), which target the EGFR receptor responsible for cancer cell growth.

In EGFR-mutated lung cancer, abnormal signaling leads to uncontrolled tumor growth. Iressa works by:

• Blocking EGFR signaling pathways
• Slowing cancer cell growth
• Improving disease control

In simple terms:
It switches off the cancer’s growth signal.

Indications

Iressa (Gefitinib) is used in:

• Non-small cell lung cancer (NSCLC)
• EGFR mutation-positive cases
• Advanced or metastatic disease

Dosage and Administration

• Standard dose: 250 mg once daily
• Taken orally
• Can be taken with or without food
• Should be taken at the same time every day
• Duration depends on clinical response

Common Side Effects

May include:

• Skin rash or dryness
• Diarrhea
• Loss of appetite
• Fatigue
• Mild nausea
• Rarely: lung or liver-related complications requiring monitoring

Monitoring During Treatment

Patients on Iressa (Gefitinib) require:

• Liver function tests
• Regular imaging scans
• Skin and respiratory symptom monitoring
• Assessment of tumor response

Availability in Egypt

Iressa (Gefitinib) is available in specialized oncology centers and major pharmacies in Egypt.

• Requires oncology supervision
• Used as part of targeted therapy protocols
• Prescription-only medication

Importance of Iressa

Iressa is important in lung cancer treatment because it:

• Directly targets EGFR mutations
• Slows tumor progression
• Improves disease control in selected patients
• Is part of global targeted therapy guidelines

Iressa (Gefitinib) 250 mg is an effective targeted therapy for EGFR-mutated non-small cell lung cancer, helping to control tumor growth and improve patient outcomes.

Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified oncology specialist.